Requip

Requip is a brand name for the medication ropinirole, which is a prescription medication used to treat Parkinson’s disease and restless legs syndrome (RLS). Here is some information about Requip:

Treatment of Parkinson’s Disease

Requip (ropinirole) is primarily prescribed for the treatment of Parkinson’s disease, a neurodegenerative disorder that affects movement. It works by acting on dopamine receptors in the brain, helping to restore dopamine levels and improve motor symptoms such as tremors, stiffness, and slowness of movement.

Treatment of Restless Legs Syndrome

Requip is also used to treat restless legs syndrome (RLS), a condition characterized by uncomfortable sensations in the legs and an irresistible urge to move them. It can help alleviate symptoms such as tingling, itching, and creeping sensations, allowing for improved sleep and reduced discomfort.

Dosage and Usage

The dosage of Requip will depend on the specific condition being treated, its severity, and individual response. It is usually started at a low dose and gradually increased to find the optimal therapeutic effect. The medication is available in different strengths and forms, including tablets and extended-release tablets.

It is important to follow the dosage instructions provided by a healthcare professional and not exceed the recommended dose. Requip is typically taken orally, with or without food, as directed by a doctor. The dosage may need to be adjusted over time based on individual response and tolerance.

Precautions and Potential Side Effects

Requip is generally well-tolerated, but like any medication, it can have potential side effects. Common side effects may include nausea, dizziness, drowsiness, low blood pressure, and hallucinations. These side effects are usually mild and may diminish over time.

In rare cases, Requip may cause more serious side effects such as severe drowsiness, compulsive behaviors, or changes in mood or behavior. It may also interact with other medications, so it is important to inform your healthcare professional about all the medications you are currently taking.

Consultation with Healthcare Professional

Requip is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor or neurologist to discuss your specific condition, determine the appropriate dosage, and assess any potential interactions or contraindications.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Requip or any other medication for the treatment of Parkinson’s disease or restless legs syndrome. They will be able to provide specific instructions based on your medical history and individual needs.

References

1. ^ Jump up to:^a b c d Tompson DJ, Vearer D (December 2007). “Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson’s disease”. Clinical Therapeutics. 29 (12): 2654–2666. doi:10.1016/j.clinthera.2007.12.010. PMID 18201581.
2. ^ Jump up to:^a b c d British National Formulary (76th ed.). Pharmaceutical Press. 2018. pp. 419–420. ISBN 978-0-85711-338-2.
3. ^ Jump up to:^{a b c d e} “Ropinirole Hydrochloride Monograph for Professionals”. Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
4. ^ “Ropinirole Pregnancy and Breastfeeding Warnings”. Drugs.com. Retrieved 3 March 2019.
5. ^ “The Top 300 of 2020”. ClinCalc. Retrieved 7 October 2022.
6. ^ “Ropinirole – Drug Usage Statistics”. ClinCalc. Retrieved 7 October 2022.
7. ^ Clinical trial number NCT00334048 at ClinicalTrials.gov – “Treating Sexual Dysfunction From SSRI Medication: a Study Comparing Requip CR to Placebo”
8. ^ Jump up to:^a b Tompson D, Hewens D, Earl N, Oliveira D, Taubel J, Swan S, Giorgi L (7–11 June 2009). An open-label, parallel-group, repeat-dose study to investigate the effects of end-stage renal disease and haemodialysis on the pharmacokinetics of ropinirole] (PDF). 13th International Congress of Parkinson’s Disease and Movement Disorders. Paris, France. Archived from the original (PDF) on 17 March 2012.
9. ^ Garcia-Borreguero D, Grunstein R, Sridhar G, Dreykluft T, Montagna P, Dom R, et al. (November 2007). “A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome”. Sleep Medicine. 8 (7–8): 742–752. doi:10.1016/j.sleep.2006.09.009. PMID 17512789.
10. ^ Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE (April 2009). “Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease”. Mayo Clinic Proceedings. 84 (4): 310–316. doi:10.4065/84.4.310. PMC 2665974. PMID 19339647.
11. ^ “What is Augmentation?” (PDF). Austin, Texas: Restless Legs Syndrome (RLS) Foundation. Archived from the original (PDF) on 9 May 2018. Retrieved 8 May 2018.
12. ^ Shill HA, Stacy M (2009). “Update on ropinirole in the treatment of Parkinson’s disease”. Neuropsychiatric Disease and Treatment. 5: 33–36. PMC 2695212. PMID 19557097.
13. ^ Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, et al. (January 1991). “Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist”. Pharmacology, Biochemistry, and Behavior. 38 (1): 147–154. doi:10.1016/0091-3057(91)90603-Y. PMID 1673248. S2CID 26842270.
14. ^ Lipp E (1 August 2008). “Novel Approaches to Lead Optimization”. Genetic Engineering & Biotechnology News. Drug Discovery. Vol. 28, no. 14. Mary Ann Liebert. p. 20. ISSN 1935-472X. Retrieved 28 September 2008. Note: The opinion that ropinirole’s use in RLS was a successful example of drug repurposes was reported as being that of Josef Scheiber, a post-doctoral fellow at the Novartis Institutes for BioMedical Research.
15. ^ Wong C (29 November 2012). “Court Rules Parkinson’s Drug Turned Straight Patient Into A Gay Sex Addict”. Huffington Post.